Dupilumab attenuate IL-4 and IL-13 synergistic effect on airway remodeling in asthma via blocking IL-4Rα/STAT6 axis - PubMed
4 hours ago
- #airway remodeling
- #IL-4/IL-13 synergy
- #dupilumab
- Dupilumab reduces IL-4 and IL-13 synergistic effect on airway fibrosis in asthma by blocking the IL-4Rα/STAT6 pathway.
- Diseased fibroblasts from asthmatic patients have higher expression of IL-4Rα/IL-13Rα1, making them more prone to activation.
- Combined IL-4 and IL-13 stimulation boosts STAT6 phosphorylation and increases collagen, fibronectin, MMP-9, and TIMP-1/2.
- IL-4 is the main driver of fibroblast proliferation.
- Dupilumab effectively inhibits this pro-fibrotic response, offering a target for treating airway remodeling in severe asthma.